Imagine needing no surgeries, experiencing none of the side-effects that come with chemotherapy or radiation, and being able ...

The team claimed that while one patient had a growth on a lymph node that had to be surgically removed following treatment, ...

"We found that some cancer types responded extremely well to the immunotherapy, including colon and stomach cancer," ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

Some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage ...

Dostarlimab offers hope in cancer treatment. Study shows tumour shrinkage in patients with mismatch repair defect. Some ...

This innovative approach challenges the standard treatment path for many cancer patients, which typically includes surgery followed by chemotherapy and radiation. For patients facing difficult ...

A New England Journal of Medicine study published April 27 found success in administering dostarlimab, an immunotherapy drug, ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

The standard surgery includes removing portions of the body where the cancer occurred. The study, conducted at Memorial Sloan ...

Investing.com -- iTeos Therapeutics, Inc. (NASDAQ: ITOS) reported a narrower-than-expected loss for the first quarter of 2025, sending its shares up 2% in response to the earnings beat.